Preventive TB therapy during pregnancy causes excessive adverse events

. . . “Identifying ways to prevent TB during pregnancy and the postpartum period is a really important way to address maternal and infant health for a globally important disease such as tuberculosis,” Amita Gupta, MD, MHS, associate professor of medicine and international health and deputy director of the Center for Clinical Global Health Education at Johns Hopkins University School of Medicine, said during a press conference here.

At the Conference on Retroviruses and Opportunistic Infections, Gupta presented safety outcomes from a randomized, double-blind, placebo-controlled phase 4 trial in which they initiated isoniazid preventive therapy (IPT) during and after pregnancy in HIV-positive women on ART in TB-endemic areas of Africa, Asia and Haiti . . .